



1 1 April 2016
2 EMA/CHMP/154812/2016
3 Committee for Medicinal Products for Human Use (CHMP)

4 **Fingolimod capsules 0.5mg product-specific**
5 **bioequivalence guidance**
6 Draft

Draft Agreed by Pharmacokinetics Working Party	February 2016
Adoption by CHMP for release for consultation	1 April 2016
Start of public consultation	2 May 2016
End of consultation (deadline for comments)	31 July 2016

7
8

Comments should be provided using this [template](#). The completed comments form should be sent to PKWPsecretariat@ema.europa.eu.

9

Keywords	<i>Bioequivalence, generics, fingolimod</i>
-----------------	--



10 Fingolimod capsules 0.5mg product-specific bioequivalence guidance

11

12 Disclaimer:

13 *This guidance should not be understood as being legally enforceable and is without prejudice to the need to ensure that the data submitted in support of a*
14 *marketing authorisation application complies with the appropriate scientific, regulatory and legal requirements.*

15 Requirements for bioequivalence demonstration (PKWP)*

BCS Classification**	BCS Class: <input type="checkbox"/> I <input type="checkbox"/> III <input checked="" type="checkbox"/> Neither of the two Background: Fingolimod may be considered a low solubility compound with complete absorption.
BE Study design <i>in case a BCS biowaiver is not feasible</i>	single dose
	parallel or cross-over
	healthy volunteers
	<input checked="" type="checkbox"/> fasting <input type="checkbox"/> fed <input type="checkbox"/> both <input type="checkbox"/> either fasting or fed
	Strength: 0.5 mg Background: 0.5mg is the only available strength
	Number of studies: one single dose study
Other critical design aspects: supra-therapeutic dose could be used for the study if considered necessary	

Analyte	<input checked="" type="checkbox"/> parent <input type="checkbox"/> metabolite <input type="checkbox"/> both
	<input type="checkbox"/> plasma/serum <input checked="" type="checkbox"/> blood <input type="checkbox"/> urine
	Enantioselective analytical method: <input type="checkbox"/> yes <input checked="" type="checkbox"/> no
Bioequivalence assessment	Main pharmacokinetic variables: AUC ₀₋₇₂ , C _{max}
	90% confidence interval: 80.00– 125.00 %

16 * As intra-subject variability of the reference product has not been reviewed to elaborate this product-specific bioequivalence guideline, it is not possible to
17 recommend at this stage the use of a replicate design to demonstrate high intra-subject variability and widen the acceptance range of C_{max}. If high intra-
18 individual variability (CV_{intra} > 30 %) is expected, the applicants might follow respective guideline recommendations.

19 ** This tentative BCS classification of the drug substance serves to define whether *in vivo* studies seems to be mandatory (BCS class II and IV) or, on the
20 contrary, (BCS Class I and III) the Applicant may choose between two options: *in vivo* approach or *in vitro* approach based on a BCS biowaiver. In this latter
21 case, the BCS classification of the drug substance should be confirmed by the Applicant at the time of submission based on available data (solubility
22 experiments, literature, etc.). However, a BCS-based biowaiver might not be feasible due to product specific characteristics despite the drug substance being
23 BCS class I or III (e.g. *in vitro* dissolution being less than 85 % within 15 min (BCS class III) or 30 min (BCS class I) either for test or reference, or
24 unacceptable differences in the excipient composition).